Guardian Pharmacy Services Files S-1/A Amendment
Ticker: GRDN · Form: S-1/A · Filed: Aug 22, 2024 · CIK: 1802255
Sentiment: neutral
Topics: ipo, registration-statement, amendment
TL;DR
Guardian Pharmacy Services filed an S-1/A, prepping for potential IPO.
AI Summary
Guardian Pharmacy Services, Inc. filed an S-1/A amendment on August 22, 2024, to its registration statement. The company, incorporated in Delaware, is a retail drug store and proprietary store (SIC code 5912). Its principal executive offices are located at 300 Galleria Parkway SE, Suite 800, Atlanta, Georgia, with a business phone number of (404) 810-0089.
Why It Matters
This filing indicates Guardian Pharmacy Services is moving forward with its public offering process, which could lead to increased capital for expansion or operations.
Risk Assessment
Risk Level: medium — As this is an S-1/A filing, it pertains to an initial public offering, which inherently carries market and execution risks.
Key Numbers
- 333-274847 — SEC File Number (Identifies the specific registration statement)
- 20240822 — Filing Date (Date the amendment was filed with the SEC)
Key Players & Entities
- Guardian Pharmacy Services, Inc. (company) — Registrant
- 300 Galleria Parkway SE Suite 800 Atlanta, Georgia (address) — Principal Executive Offices
- (404) 810-0089 (phone_number) — Business Phone
- Fred P. Burke (person) — President and Chief Executive Officer
- Delaware (jurisdiction) — State of Incorporation
- 5912 (sic_code) — Standard Industrial Classification
FAQ
What is the primary purpose of this S-1/A filing?
This S-1/A filing is an amendment to the initial Form S-1 registration statement, indicating updates or additions to the information provided for a potential public offering.
When was Guardian Pharmacy Services, Inc. incorporated?
The filing indicates the company is incorporated in Delaware.
Who is the President and CEO of Guardian Pharmacy Services, Inc.?
Fred P. Burke is listed as the President and Chief Executive Officer.
What is the business address of Guardian Pharmacy Services, Inc.?
The business address is 300 Galleria Parkway SE, Suite 800, Atlanta, Georgia.
What is the Standard Industrial Classification (SIC) code for Guardian Pharmacy Services, Inc.?
The SIC code is 5912, which corresponds to Retail - Drug Stores and Proprietary Stores.
Filing Stats: 4,462 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2024-08-22 17:17:32
Key Financial Figures
- $68 million — ave built this business with a total of $68 million of cash invested as equity capital and
- $1.1 b — evenue through June 30, 2024 surpassing $1.1 billion, we have modest debt and we are c
- $1.046 b — or the year ended December 31, 2023 was $1.046 billion, compared to $908.9 million for t
- $908.9 million — 1, 2023 was $1.046 billion, compared to $908.9 million for the year ended December 31, 2022, o
- $37.7 m — or the year ended December 31, 2023 was $37.7 million, compared to $49.7 million for th
- $49.7 million — 31, 2023 was $37.7 million, compared to $49.7 million for the year ended December 31, 2022, a
- $76.2 m — or the year ended December 31, 2023 was $76.2 million, compared to $65.7 million for th
- $65.7 million — 31, 2023 was $76.2 million, compared to $65.7 million for the year ended December 31, 2022. I
- $575.4 m — track record of growth, with revenue of $575.4 million, net income of $22.9 million, Adj
- $22.9 m — evenue of $575.4 million, net income of $22.9 million, Adjusted EBITDA of $41.9 million
- $41.9 million — me of $22.9 million, Adjusted EBITDA of $41.9 million and residents served of approximately 1
- $52.0 million — 4, we have modest leverage with debt of $52.0 million. We have long believed in promoting emp
- $24.8 billion — market revenues would be approximately $24.8 billion in 2024. The U.S. institutional pharmac
Filing Documents
- d856029ds1a.htm (S-1/A) — 1690KB
- d856029dex104f.htm (EX-10.4(F)) — 42KB
- d856029dex104g.htm (EX-10.4(G)) — 863KB
- d856029dex211.htm (EX-21.1) — 20KB
- d856029dex231.htm (EX-23.1) — 1KB
- d856029dex232.htm (EX-23.2) — 1KB
- g856029g01s11.jpg (GRAPHIC) — 127KB
- g856029g04k04.jpg (GRAPHIC) — 159KB
- g856029g05t69.jpg (GRAPHIC) — 139KB
- g856029g08a09.jpg (GRAPHIC) — 198KB
- g856029g11i66.jpg (GRAPHIC) — 77KB
- g856029g11l83.jpg (GRAPHIC) — 975KB
- g856029g18c77.jpg (GRAPHIC) — 174KB
- g856029g50k65.jpg (GRAPHIC) — 111KB
- g856029g50w50.jpg (GRAPHIC) — 217KB
- g856029g60a01.jpg (GRAPHIC) — 113KB
- g856029g64h76.jpg (GRAPHIC) — 186KB
- g856029g70l27.jpg (GRAPHIC) — 106KB
- g856029g76a04.jpg (GRAPHIC) — 79KB
- g856029g79n59.jpg (GRAPHIC) — 105KB
- g856029g85p03.jpg (GRAPHIC) — 88KB
- g856029g95i98.jpg (GRAPHIC) — 93KB
- 0001193125-24-205420.txt ( ) — 6630KB
Risk Factors
Risk Factors 24 Special Note Regarding Forward-Looking Statements 45 Corporate Reorganization 47
Use of Proceeds
Use of Proceeds 50 Dividend Policy 51 Capitalization 52
Managements Discussion and Analysis of Financial Condition and Results
Managements Discussion and Analysis of Financial Condition and Results of Operations 56
Business
Business 70 Management 103
Executive Compensation
Executive Compensation 113 Director Compensation 123 Certain Relationships and Related Party Transactions 124
Security Ownership of Certain Beneficial Owners and
Security Ownership of Certain Beneficial Owners and Management 126
Description of Capital Stock
Description of Capital Stock 128 Shares Eligible for Future Sale 135 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 137
Underwriting
Underwriting 142 Legal Matters 150 Experts 150 Where You Can Find More Information 150 Index to Consolidated Financial Statements F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus that we have filed with the Securities and Exchange Commission (the SEC). Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the Class A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of our Class A common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are offering to sell, and seeking offers to buy, our Class A common stock only in jurisdictions where such offers and sales are permitted. For investors outside the United States, neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside the United States who come into possession of this prospectus and any free writing prospectus related to this offering are required to inform themselves about, and to observe any restrictions related to, the offering of the shares of our Class A common stock and the distribution of this prospectus and any such free writing prospectus outside of the United States. i Tabl